FDA Inspection 1177888 — Andrew Rezvani, M.D.

Andrew Rezvani, M.D. — FEI 3022952263

The FDA completed an inspection of Andrew Rezvani, M.D. on August 19, 2022 in Palo Alto, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
August 19, 2022
Fiscal Year
2022
Product Type
Biologics
Project Area
Bioresearch Monitoring
Location
Palo Alto, CA (United States)

Additional Details

Clinical Investigator (CI)

Citations

IDCFRDescription
756021 CFR 312.60FD-1572, protocol compliance